DYNLT3 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 non-small cell lung cancer cell line, engineered for loss-of-function studies of the DYNLT3 gene. This product features a polyclonal mixture of gene-disrupted cells, providing a heterogeneous knockout model that reflects diverse editing outcomes without monoclonal selection. It is designed for researchers requiring robust, pooled functional analyses of DYNLT3-dependent processes in a lung adenocarcinoma context.
The NCI-H1975 host cell line is a human lung adenocarcinoma epithelial line derived from a female non-smoker. It harbors activating EGFR L858R and T790M mutations, rendering it sensitive to first- and third-generation EGFR tyrosine kinase inhibitors and widely used to study oncogenic signaling and acquired drug resistance. These genetic features make NCI-H1975 an ideal model for investigating molecular mechanisms in EGFR-driven non-small cell lung cancer.
DYNLT3 (Tctex-1) encodes a light chain component of the cytoplasmic dynein complex, a minus-end-directed microtubule motor essential for intracellular transport, mitotic spindle organization, and cell division. DYNLT3 interacts with dynein heavy chains (DYNC1H1, DYNC2H1) and light chains (DYNLL1, DYNLRB1) to assemble the active motor complex. It is regulated by the mitotic kinases PLK1 and CDK1 through phosphorylation, modulating dynein function during mitosis. Downstream, DYNLT3 facilitates transport of cargo adaptor proteins and mitotic checkpoint regulators, working in concert with dynactin, LIS1, and NDE1 to ensure proper chromosome segregation and cell cycle progression.
In the NCI-H1975 background, DYNLT3 knockout provides a powerful tool to dissect dynein-mediated processes in EGFR-mutant lung cancer. Disruption of this light chain is expected to impair retrograde transport and mitotic spindle assembly, potentially leading to mitotic defects that sensitize cells to spindle assembly checkpoint inhibitors or EGFR-targeted therapies. The polyclonal nature preserves genetic diversity, enabling exploration of synthetic lethal interactions and resistance mechanisms relevant to non-small cell lung cancer.
These polyclonal knockout cells are suitable for a broad range of assays, including western blotting to confirm DYNLT3 protein loss, immunofluorescence to assess mitotic spindle and organelle distribution defects, live-cell imaging of vesicle transport dynamics, and cell proliferation or migration/invasion studies. They also enable EGFR inhibitor drug sensitivity profiling to investigate links between dynein function and therapeutic response. This model supports high-content screening and mechanistic investigations in cancer biology. For further technical information, please contact Ascent Research.
